A single patient does not constitute proof of efficacy. Jessi's progress can be shared with whomever they want
The scaffold may help the spinal cord heel in a position such that more connections can reestablish. The reestablishment of these connections may take time ... perhaps after the scaffold is gone. It's all speculation at this point and you certainly cannot say the improvement is not related to the scaffold. The animal studies certainly suggest that function after injury is better when the scaffold is used.
Starting in June. We could have results very quickly.... like 1 year or less.
Why do you keep on bumping this meaningless message. OCAT sells shares to Lincoln based the price from the previous 10 days or so. This is nothing new. Been doing this for at least a couple of years.
Why don't we just make up a bunch of conspiracies to explain this. That will make us feel better.
A message board poster's credibility goes to ZERO when they start spouting the conspiracy that shorts are using to Yahoo MB to manipulate the stock.
Maxim's credibility is about the same as the unqualified clowns that put out garbage on Seeking Alpha. I own a lot of CUR and a little NVIVD. The data, though limited, so far on the scaffold is pretty impressive. A patient recovering like patient #1 is about 1 in 10. If the same happens for patient #2 the odds are 1 in 100 of it not being the scaffold. If the next 3 patients see improvement they could get approval quickly if the FDA agrees that this is a device. I think the large increase in market cap for NVIVD has to do with how quickly they might receive approval.
They have already had all Imetelstat development transferred to J&J. No need to "Opt In" until the contract stipulates that they need to make a choice.
Appreciate your message. Patience is needed to watch the full potential of Imetelstat play out. Let's hope Chip doesn't sell out too soon.
Great question. Perhaps NVIV doesn't even have the answer to this question. But it sounds logical to remove the scare tissue and put on the scaffold.
Not a peep about Geron. He just launches into his boiler plate pump of ARWR. Is this and auto pump alias ?
Dog face. Go bark under a different tree. You are a STEM pumping fool.
Kolbert has an awful track record. He recommend selling CUR at 80 cents and recommended a buy on STEM at the same time when it was $1.70.
byecell. The second patient improving is huge in my view. If 10% of "complete" injury SCI patients experience improvement below the injury site then there was a 1 and 10 chance that it was not the scaffold with Jordan. Now with 2 patients simple statistics would show it is now a 1 and 100 chance that is was not the scaffold. Now lets see what happens with #3, 4 and 5. It could be a grand slam